The Cognitive Neuroscience Journal

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
The Cognitive Neuroscience Journal 44 7897 074717

Current Treatments For Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disease disabling communication between the brain and spinal cord (central nervous system) by attacking the protective sheath (myelin) that covers the nerve fibers which allows electrical impulses to transmit rapidly and effectively along the nerve cells. Symptoms include fatigue, vision loss, pain and impaired coordination. Ocrelizumab-The FDA approved a groundbreaking new drug in 2017 for the treatment of relapsing MS. The drug is also the first approved to treat PPMS. Other category of drugs includes IV steroids, glucocorticoids, Disease-Modifying Drugs, Off-Label Drugs, Deep Brain Stimulation, plasmapheresis. The symptoms duration and severity may vary from person to person, some may not exhibit any symptoms for most of their lives, while others can have severe, chronic symptoms that never go can last for years or be life-long. Immunosuppressant and physiotherapy can help with symptoms and slow disease progression. Treatment can help, but this can't be cured.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Neurology & Psychology

Get the App